AMS at a Glance
Advanced Medical Solutions Group plc is a leading developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced woundcare markets.
Our primary focus is to create quality outcomes for our:
Full Year Period End31 December 2019
Interim Dividend Payment25 October 2019
Interim Results Announcement11 September 2019
Half Year Period End30 June 2019
Final Dividend Payment14 June 2019
Annual General Meeting5 June 2019
Preliminary Results Announcement13 March 2019
AMS will attend the 10th Annual Jefferies London Healthcare Conference on 20 November 2019. In 2018, the conference hosted 500 participating... Read More
Latest Financial Highlights
This has been another period of growth for the Group despite the downturn in US LiquiBand® sales. Revenue increased by 2% to £48.7 million and by 1% at constant currency with continued good results from the majority of our geographies and product ranges. Excluding US LiquiBand®, Group sales increased by 10% on both a reported and constant currency basis.
Surgical revenues were impacted by a shortfall in US LiquiBand® sales and decreased by 3% (4% at constant currency) to £26.5 million (2018 H1: £27.3 million). In contrast, Woundcare revenues increased by 9% (8% at constant currency) to £22.2 million (2018 H1: £20.3 million) as a result of increased partner demand for antimicrobial dressings in Infection Management.
At the start of 2019, we made some adjustments to our Business Unit structure to better manage our different surgical and advanced woundcare opportunities and to optimise the Group’s routes to market. We are pleased this is having the desired effect on woundcare and we believe that with our two individual business units we are now optimally positioned to drive growth for the future
Despite the challenging conditions experienced across our sector, we are pleased that the Group continues to see significant growth opportunities in our surgical and woundcare ranges. Whilst a slow-down in our progress with US LiquiBand® affected our overall Surgical growth during the period, the performance of our range in all other key markets and regions continues to be very strong.
In January 2019, AMS announced the acquisition of Sealantis for US$25 million. Sealantis’ products, which reduce leakage of blood or fluid in high-risk surgery, provide AMS with access to the growing $1 billion internal sealants market. Integration is progressing well and is largely complete. We expect to start clinical trials on target at around the end of 2019 to support first product launches for gastrointestinal surgery in 2021 with further innovations to follow in subsequent years.